Company intelligence / Profile preview

EmitBio Inc.

Durham, North Carolina, United Statesemitbio.com ↗

Ownership: Private
Employees: ~14
Development stage: Phase 3

Overview

EmitBio has conducted a sham-controlled dose-finding study of 216 subjects across multiple clinical sites in the US, evaluating their RD-X19 device. The device was well-tolerated and showed promising results in improving symptomatic relief, particularly in subjects aged 40 years and above with mild COVID-19. Laboratory studies have shown the technology can eliminate 99.99% of Omicron and Delta variants in lab settings[3][7].

Therapeutic areas: Infectious Diseases
Modalities: Light-based therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

RD-X19

Phase 3

Indications: COVID-19, Long COVID, RSV, Influenza

Beyond the preview

Go deeper on EmitBio Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EmitBio Inc..

Explore the full profile